Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Mode of action

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

PLAY VIDEO

In pain interface

In pain interface

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

VIEW NOW

Welcome

Palexia is a strong centrally acting analgesic.1 Palexia combines two complementary mechanisms of action in a single molecule and targets both nociceptive and neuropathic pain.2,3 Palexia provides comparable pain relief with superior QoL outcomes compared to oxycodone controlled release (CR).5

Find out more about the efficacy and tolerability Palexia can offer your patients suffering from acute or chronic pain.
KOL video bank highlights

KOL video bank highlights

Coming soon.

 

 

 

 

 

Prescribing Information can be accessed by clicking here or on the PI button at the bottom of each page.

Adverse events should be reported. Please contact your local adverse event reporting authority should you experience an adverse event. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Grunenthal on 0870 351 8960.

If you would like to be sent updates on palexia.co.uk and content updates please tick the box and provide
your e-mail address below.

I would like to receive updates on Palexia and palexia.co.uk content updates.
 
Please keep me updated with new information on pain treatments.
Please notify me about meetings in my area.
I am interested in contributing content to palexia.co.uk.

References:

  1. Palexia SR, Summary of Product Characteristics. February 2011.
  2. Kress HG. Eur J Pain 2010; 14(8): 781-3.;;;
  3. Tzschentke TM et al. Drugs Today 2009; 45(7): 483-96.
  4. Tzschentke TM et al. J Pharmacol Exp Ther 2007; 323(1): 265-76.
  5. Lange B et al. Adv Ther 2010; 27(6): 381-99.

P12 0067
Date of preparation: March 2012